Healthcare & Life Sciences
Cut Research Timelines. Reduce Development Costs.
Every week saved in analysis is a week closer to market. Life sciences teams routinely significantly reduce research analysis time while maintaining regulatory-grade rigor.
Accelerate Every Stage of Development
Compress Analysis Timelines Dramatically
Process patient and HCP feedback in hours, not weeks. Faster analysis means faster go/no-go decisions and shorter development cycles.
Reduce Research Spend
Cut the cost of qualitative analysis without sacrificing depth. Reallocate budget to additional studies or larger sample sizes.
De-Risk Launch Decisions
Synthesize KOL and HCP insights faster. Better market intelligence means better positioning and reduced commercial risk.
Maintain Compliance ROI
Audit-ready outputs from day one. Avoid costly rework and delays from compliance issues downstream.
The High Cost of Slow Insights in Drug Development
Pharmaceutical and biotech companies operate under brutal time pressure. Every day a drug remains in development is a day of lost revenue potential and a day closer to patent expiration. Yet the insights that drive go/no-go decisions-patient feedback, HCP perspectives, KOL input-often take weeks to synthesize.
Traditional qualitative analysis creates bottlenecks in Phase II and III trials. Research teams collect hundreds or thousands of open-ended responses from patients, caregivers, and healthcare professionals. Coding and theming this feedback manually takes experienced analysts 40-80 hours per study. By the time insights reach decision-makers, the window to adjust protocols or messaging may have closed.
The Compounding Impact:
- • Delayed decisions push back launch timelines by months
- • Missed signals in early feedback lead to expensive pivots later
- • Limited sample sizes due to high analysis costs reduce statistical power
- • Shallow insights from rushed analysis miss competitive differentiators
PetaSight dramatically accelerates qualitative analysis while maintaining regulatory-grade rigor. The same patient feedback that took weeks to code now takes days. The same KOL interviews that required many hours of analyst time now requires much less. This speed enables life sciences teams to run larger studies, iterate faster, and make better-informed decisions throughout the development lifecycle.
Regulatory-Grade AI for Life Sciences Research
Speed means nothing if it compromises compliance. PetaSight builds AI analysis workflows specifically designed for FDA, EMA, and ICH regulatory environments. Every output is audit-ready from day one.
Audit Trail & Documentation
Regulatory bodies demand transparency in how conclusions are reached. Our platform captures:
- • Complete version history of analysis decisions
- • Training data provenance and model lineage
- • Analyst review and approval timestamps
- • Source text to coded theme mappings
Validation & Verification
AI-assisted does not mean unvalidated. Every project includes:
- • Human-in-the-loop review for critical classifications
- • Inter-rater reliability checks against gold standard coding
- • Statistical validation of thematic consistency
- • Documentation of model performance metrics
Proven in Regulatory Submissions: Our clients have successfully included AI-assisted analysis in multiple IND and NDA submissions. Regulatory reviewers consistently accept our audit trails and validation documentation without issue.
From Patient Voice to Strategic Insight
Phase II: Early Signal Detection
In early clinical trials, patient feedback provides critical signals about tolerability, efficacy perception, and quality of life impact. Traditional manual coding of this feedback takes 2-3 weeks, delaying protocol amendments or stopping decisions.
With PetaSight: Synthesize patient feedback from 50-100 participants in 2-3 days. Identify adverse event patterns, dosing concerns, and quality-of-life impacts while there's still time to adjust trial protocols. This faster feedback loop reduces the risk of late-stage failures.
Phase III: Endpoint Validation & Commercial Prep
Phase III generates massive volumes of qualitative data-patient-reported outcomes, caregiver diaries, open-ended symptom descriptions. Analysis of this data informs both clinical endpoints and commercial positioning.
With PetaSight: Process 500-1000 patient narratives in under a week. Identify the language patients use to describe benefits, which resonates in future marketing materials. Detect safety signals that might impact label language. Generate insights that shape both regulatory filings and market positioning simultaneously.
Post-Launch: Real-World Evidence & HCP Insights
After launch, ongoing monitoring of patient forums, HCP feedback, and real-world evidence studies generates continuous qualitative data. This feedback informs label expansions, lifecycle management, and competitive responses.
With PetaSight: Continuous analysis of patient community discussions and HCP feedback. Early detection of off-label use patterns, unmet needs in current indications, and competitive threats. Transform passive monitoring into proactive strategic intelligence.
See the timeline and cost impact.
Calculate how much faster you could move - and how much you could save - with AI-powered research analysis.